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Abstract A three-dimensional (3D) scaffolding system
for chondrocytes culture has been produced by agglom-
eration of cells and gelatin microparticles with a mild
centrifuging process. The diameter of the microparticles,
around 10 l, was selected to be in the order of magnitude
of the chondrocytes. No gel was used to stabilize the
construct that maintained consistency just because of cell
and extracellular matrix (ECM) adhesion to the substrate.
In one series of samples the microparticles were charged
with transforming growth factor, TGF-b1. The kinetics of
growth factor delivery was assessed. The initial delivery
was approximately 48 % of the total amount delivered up
to day 14. Chondrocytes that had been previously
expanded in monolayer culture, and thus dedifferentiated,
adopted in this 3D environment a round morphology, both
with presence or absence of growth factor delivery, with
production of ECM that intermingles with gelatin parti-
cles. The pellet was stable from the first day of culture.
Cell viability was assessed by MTS assay, showing higher
absorption values in the cell/unloaded gelatin micropar-
ticle pellets than in cell pellets up to day 7. Nevertheless
the absorption drops in the following culture times. On
the contrary the cell viability of cell/TGF-b1 loaded
gelatin microparticle pellets was constant during the
21 days of culture. The formation of actin stress fibres in
the cytoskeleton and type I collagen expression was sig-
nificantly reduced in both cell/gelatin microparticle pellets
(with and without TGF-b1) with respect to cell pellet
controls. Total type II collagen and sulphated glycos-
aminoglycans quantification show an enhancement of the
production of ECM when TGF-b1 is delivered, as
expected because this growth factor stimulate the chon-
drocyte proliferation and improve the functionality of the
tissue.
1 Introduction
A three-dimensional (3D) arrangement of cells in an ade-
quate substrate seems to be a requirement for the devel-
opment and maintenance of the phenotype of hyaline
cartilage chondrocytes [1]. Mature chondrocytes can be
isolated from the cartilage tissue obtained in a biopsy of
articular cartilage. When they are plated in monolayer
culture on plastic substrates, they can grow to the cell
numbers required for tissue regeneration but they loose
their native phenotype showing clear changes in cell
morphology and expression of type I collagen which is
nearly absent in articular cartilage tissue [2]. The re-dif-
ferentiation of these cells in 3D cultures is thus a subject of
great interest for cartilage engineering.
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A huge number of different 3D scaffolding systems have
been proposed for cartilage engineering including sponges,
fibber meshes, gels and microparticles [3] with varying
materials of synthetic or natural origin and a variety of pore
architecture. Among them, 3D arrangements obtained by
fusion of microparticles as scaffolding blocks have been
investigated [3]. The drawback of these systems is that
global porosity is not high enough for cell survival, and the
strong linkage between particles allows few spaces for
production and accumulation of ECM components. On the
other hand, the interest in developing injectable scaffolding
systems yielded to explore a number of combinations
of synthetic microparticles and ‘‘in situ’’ crosslinkable
hydrogels [4–8].
Gelatin microparticles (Gel-MCP) have been explored
extensively as drug or growth factor delivery systems. In
particular they have been used for delivery of TGF-b1 or
TGF-b3 growth factors in ‘‘in vitro’’ chondrogenic dif-
ferentiation of bone marrow mesenchymal stem cells.
TGF-b3 loaded Gel-MCP were mixed with cells to form a
pellet by centrifugation, labelling as a modified pellet by
Fan et al. [9]. A small amount of microparticles was used
in that work in order to preserve the large cell to cell
contact that favours chondrogenic differentiation of mes-
enchymal stem cells. Han et al. [10] used a mixture of
gelatin and chitosan microparticles with the same purpose,
while Park et al. [11] used a hydrogel to entrap both
cells and Gel-MCP. A similar construct was proposed by
Hu et al. [12] who introduced microparticles and chon-
drocytes in a chitosan hydrogel. Gelatin has been also
used to functionalize microparticles made of synthetic
biodegradable polyester such as polylactide/polyglycolide
copolymers, PLGA, [13].
On the other hand Gel-MCP have been used as
microcarriers for chondrocyte expansion in stirring biore-
actors. It was shown that human nasal chondrocytes
expanded on the surface and in the micropores of the
microcarriers maintain the ability to differentiate to hya-
line cartilage chondrocytes in pellet culture [14]. These
microcarriers have been used in spinner flasks as well [15,
16]. Gelatin has been also used to fabricate macroporous
scaffolds for cartilage engineering profiting the capacity of
delivering growth factors from the scaffold itself [17].
Although the mentioned works show that gelatin is a
suitable substrate for chondrocyte 3D culture none has
proved to be the ultimate solution. Results obtained from
tissue engineering procedures suggest that the proposed
gelatin scaffolding systems may lead to a mixture of
hyaline and fibrocartilage tissue.
In our work we explore the use of Gel-MCP not only as
a growth factor delivery vehicle but also as a 3D scaf-
folding system. Dedifferentiated chondrocytes are mixed
with microparticles at a Gel-MCP/cells ratio high enough
to form a construct in which cells are surrounded by the
gelatin as the scaffolding material. In addition in one of the
experimental series Gel-MCP will be loaded with TGF-b1
which is delivered continuously during ‘‘in vitro’’ culture.
It will be shown that Gel-MCP can agglomerate in situ by
the action of the cells; the particles thus provide a 3D
structural support for cells which is able to release relevant
bioactive molecules at the same time.
2 Materials and methods
2.1 Preparation of unloaded and TGF-b1 loaded Gel-
MCP
Crosslinked Gel-MCP encapsulating TGF-b1 growth fac-
tor were prepared by emulsification solvent extraction and
crosslinking method [18]. Briefly, 1 g of gelatin (Scharlab,
Spain) was dissolved in 10 mL of Dulbecco’s phosphate
buffer solution (DPBS) at 50 C to a final concentration of
10wt. %. Subsequently, gelatin solution was cooled to
37 C, mixed with the TGF-b1 (Sigma, Spain) solution
(20 lg/mL) and homogenized. Then, the mixture was
added into olive oil at a feeding rate of 1 mL/min under
stirring at 1,500 rpm for 30 min. After this time, 10 mL of
20 mM genipin (Wako Chemical, Japan) solution was
added into the biphasic system at a rate of 1 mL/min and
maintained under stirring for 17 h. Finally, loaded cross-
linked Gel-MCP were collected by centrifugation, washed
several times in acetone to remove residual olive oil and
lyophilised. The loaded microparticles were stored at
-20 C until further use. Unloaded crosslinked Gel-MCP
were also prepared and used as reference. The percentage
yield of the lyophilized TGF-b1 loaded Gel-MCP cross-
linked with genipin was calculated dividing the weight of
microparticles obtained by initial weight of gelatin used.
The unloaded Gel-MCP were obtained using the same
procedure, without add TGF-b1 in the gelatin solution.
2.2 Determination of crosslinking degree
Ninhydrin (NHN) assay [19] was used to determine the
percentage of free amino groups remaining in the Gel-MCP
after crosslinking reaction. Ninhydrin (Sigma-Aldrich,
Spain) solution was freshly prepared on the day of the
assay dissolving 0.8 g of NHN and 0.12 g of hydrindantin
(Sigma-Aldrich, Spain) in 40 mL of ethylene glycol
(Sigma-Aldrich, Spain). This solution was then mixed with
lithium acetate buffer (4 M, pH 5.2) to prepare the working
reagent. For the assay, 0.5 mg of lyophilized Gel-MCP
(uncrosslinked and crosslinked with genipin) was mixed
with 0.5 mL of working reagent in eppendorf tubes. Then,
the tubes were immediately capped, shaken and heated to
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100 C in a water bath for 30 min to allow the reaction to
proceed. The solution was then cooled down to room
temperature, diluted with 5 mL of 50 % isopropanol and
vortexed for 15 s in order to oxidise the excess of
hydrindantin. The absorbance of each solution was mea-
sured at 570 nm using a UV spectrophotometer (Cecil
CE9200, UK). The amount of free amino groups in the
assayed microparticles was determined by a calibration
curve of glycine (n = 5). The crosslinking degree was
calculated according to the Eq. 1.
Crosslinking degree ¼
NHN reactive amineð Þfresh NHN reactive amineð Þfixed
h i
NHN reactive aMineð Þfresh
 100
ð1Þ
where, ‘‘fresh’’ is the mole fraction of free NH2 groups in
the uncrosslinked and unloaded Gel-MCP and ‘‘fixed’’ is
the mole fraction of free NH2 groups remaining in the
unloaded Gel-MCP after the crosslinked reaction with
genipin.
2.3 Determination of encapsulation efficiency (EE)
The EE of the TGF-b1 loaded Gel-MCP crosslinked with
genipin was expressed as the percentage of the TGF-b1
amount in the microparticles with respect to the initial
TGF-b1 used. For that, 2 mg of TGF-b1 loaded Gel-MCP
were swelled in DPBS and centrifuged at 15,000 rpm for
30 min, three times, in order to extract the TGF-b1 from
the Gel-MCP (n = 5). The supernatant was extracted and
the TGF-b1 was quantified by an enzyme-linked immu-
nosorbent assay kit (R&D systems, USA).
2.4 Morphological analysis
The morphology of unloaded gelatin and TGF-b1 loaded
Gel-MCP were examined by scanning electron microscopy
(SEM) (Jeol JSM-5410, Japan). All samples were coated
with a conductive layer of sputtered gold. The micrographs
were taken at an accelerating voltage of 15 kV in order to
ensure a suitable image resolution. Microparticle size dis-
tribution was determined analysing 10 different images,
with around 30 microparticles in each one.
2.5 Water uptake studies
The water uptake of Gel-MCP was determined by
immersion in distilled water at 37 C for 24 h. The weight
of the dry and swollen microparticles was measured and
the water uptake (W) was calculated using the following
equation:
W ¼
weight of swollen Gel  MCP  weight of dry Gel  MCPð Þ
weight of dry Gel  MCP  100
ð2Þ
Uncrosslinked microparticles were also prepared and
were used as control in the water uptake studies (n = 5).
The appearance of swollen crosslinked and uncrosslinked
Gel-MCP were observed using an optical microscope
(ECLIPSE-E6000, Nikon, Japan).
2.6 In vitro release studies
The in vitro release profile of TGF-b1 from Gel-MCP was
examined over 14 days. The microparticles were dispersed
into 1 mL of DPBS (pH 7.4). These dispersions were
immediately placed in an orbital shaker water bath at 37 C
and were shaken at a frequency of 60 rpm. After 0.04, 0.08,
0.125, 0.16, 0.20, 1, 2, 4, 7, 10 and 14 days, the micro-
particle suspension was centrifuged at 5,000 rpm to collect
the supernatant for analysis (n = 8). The amount of TGF-
b1 in the supernatant was measured using an enzyme-
linked immunosorbent assay kit (eBioscience, USA).
2.7 Cell isolating and seeding
Chondrocytes were isolated from human articular cartilage
from the knee of a patient undergoing total knee arthro-
plasty by standard protocols [20] and in accordance with the
Declaration of Helsinki of 1975 as revised in 1983, and
approved by our local Ethical Committee. All subjects
provided a written informed consent before their inclusion
in the study. The chondrocytes used in this study were
supplied by IMIM (Institut Municipal d’Investigacio´
Me`dica, Barcelona, Spain). Cells were plated in culture
flasks (Nunc, Spain) at high density in Dulbecco’s Modified
Eagle’s Medium (DMEM) supplemented with 10 % fetal
bovine serum (FBS) (both reagents supplied by Gibco, UK)
and 50 lg/mL ascorbic acid (Sigma-Aldrich, Spain) at
37 C in a 5 % CO2 humidified atmosphere. The culture
medium was renewed every 2-3 days. After 5 days,
adherent cells were enzymatically harvested with tripsin/
EDTA (Gibco, UK) and seeded on the Gel-MCP, as control
sample, and TGF-b1 loaded Gel-MCP at cell density of
2.5 9 105 cells/tubes. To obtain the cell/Gel-MCP pellets
(with and without TGF-b1), tubes that contained 20 mg of
loaded or unloaded Gel-MCP and chondrocytes were cen-
trifuged at 300 g 9 5 min. Cell pellets without any sample
were used as reference. The experiments were conducted
for 3 weeks in chondrogenic media consisting of Dul-
becco’s high glucose modified Eagle medium with 1 %
ITS ? Premix (DB Biosciences, USA), 100 lg/mL sodium
pyruvate (Gibco, UK), 1 % L-glutamine (Gibco, UK),
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100 lg/mL penicillin–streptomycin (Lonza, USA) supple-
mented with 50 lg/mL ascorbic acid (Sigma-Aldrich,
Spain). The culture medium was replaced three times/week.
2.8 Cell adhesion and morphology
Chondrocyte adhesion and morphology were investigated
by scanning electron microscopy, SEM (Jeol JSM-5410,
Japan). For this purpose, cell/gel-MCP pellets (with and
without TGF-b1) and cell pellets samples were removed
from the culture medium at different times (1, 7, 14 and
21 days), washed in PBS, fixed in 2.5 % glutaraldehyde,
rinsed twice with PBS and dehydrated in series of ethanol
solution (30, 50, 70, 90 % and absolute) for 15 min with
final dehydration in absolute ethanol for 30 min. Finally,
samples were dried at room temperature and sputter coated
with gold using a Fisons Instrument Coater (Polaron SC
502, UK) before observation with SEM.
2.9 Cell viability
The viability of chondrocytes cultured for 1, 7, 14 and
21 days was determined using the MTS (3-(4,5-dimethyl-
thiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium) assay following manufacturer instructions
(Promega, Spain). The samples were washed twice with PBS
and incubated with fresh culture medium without phenol red
and FBS containing MTS reagent (ratio 5:1) at 37 C for 3 h
in darkness. After the incubation period, the absorbance was
quantified by spectrophotometry at 490 nm with a microplate
reader (VICTOR3TM, PerkinElmer, USA). The background
absorbance values obtained from unseeded gelatin micro-
particle pellets (with and without TGF-b1) were subtracted to
the seeded pellets absorbance values to get the final viable
cell number.
2.10 Immunofluorescence
Aggrecans and type I collagen were detected by immuno-
fluorescence assays. Cell/Gel-MCP pellets (with and
without TGF-b1) with 8 mm of diameter were fixed with
formalin and sectioned in slices (*2 mm), washed with
PBS twice and permeabilized with 0.1 % v/v Triton X-100
in PBS. The cell pellet of 1 mm of diameter was fixed and
washed as previously described. Afterwards, all samples
were incubated with 10 % fetal bovine serum in PBS
blocking solution for 2 h at room temperature. Then,
samples were incubated in the dilute primary antibody
solution (Mouse anti-Human Aggrecan and Rabbit anti-
human Type I Collagen, 1:50, from Invitrogen, Spain and
Chemicon, Spain respectively) overnight at 4 C, samples
were washed again three times in PBS and then incubated
with the respective secondary fluorochrome-conjugated
antibody (1:200) for 2 h at room temperature in dark. Also,
the formation of actin cytoskeleton was visualized using
bodipy FL phallacidin (Invitrogen, Spain). Finally, samples
were washed three times with PBS and mounted with a
drop of mounting medium containing DAPI for nuclei
staining (blue).
2.11 Biochemical analysis
The type II collagen secreted by the chondrocytes were
determined quantitatively using type II Collagen Elisa kit
(MD Bioproducts, USA) after pepsin digestion of cell/Gel-
MCP pellets (with and without TGF-b1) and cell pellets
(n = 5) according to the supplier’s instructions. Using
500 lL of digested solution, GAG content was quantified
following instructions provided by the manufacturer in the
Blyscan_Sulfated Glycosaminoglycan Assay kit (Biocolor
Ltd., UK). Bound dye values were quantified at 656 nm
using a microplate reader (VICTOR3TM, PerkinElmer,
USA).
2.12 Statistical analysis
Data were expressed as mean values ± standard deviation
(SD) of the mean (mean ± SD) and analysed by one-way
analysis of variance (ANOVA) and Student’s t test. The
level of statistical significance was set as P \ 0.05.
3 Results
3.1 Characterization of Gel-MCP
The yield of Gel-MCP (with and without TGF-b1) was
around 90 %. The crosslinking degree through NHN assay
was determined in order to know the quantities of free NH2
remaining in the Gel-MCP after the reaction with genipin.
The obtained results indicate that a 74 % free NH2 remain
in the gelatin chemical structure.
The EE has a strong dependency with the preparation
technique used to synthesize the microparticles. The TGF-
b1 loaded Gel-MCP crosslinked with genipin retain more
than 85 ± 1 % of the TGF-b1 initially used.
The morphology of Gel-MCP (with and without TGF-
b1) was examined by SEM (Fig. 1). The microparticles
showed a spherical morphology of all samples with slightly
roughness surface without wrinkles or cracks. On the other
hand, the microparticles have a homogeneous size, ranging
from 6 to 24 lm in diameter with a mean diameter size in
both cases (microparticles with and without TGF-b1) of
12 lm (see Fig. 1).
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3.2 Water uptake experiments
Figure 2 shows the morphological appearance of the non-
crosslinked (a,b) and crosslinked (c,d) Gel-MCP in dry and
wet state. After 24 h, the water uptake of the crosslinked Gel-
MCP (111.5 ± 12.5 %) significantly decrease compared with
the values of the non-crosslinked ones (325.3 ± 11.1 %).
3.3 In vitro TGF-b1 release study
After the encapsulation process, 38.4 ng of TGF-b1 were
loaded in 20 mg of Gel-MCP. The accumulative release
profile of TGF-b1 from the Gel-MCP crosslinked with
genipin over 14 days at 37 C in D-PBS was represented in
Fig. 3. TGF-b1 release pattern showed a burst until 24 h,
Fig. 1 Morphology and particle
size distribution of crosslinked
Gel-MCP without (a, c) and
with (b, d) TGF-b1
Fig. 2 Gross appearance of non-crosslinked (a, b) and crosslinked (c, d) Gel-MCP in dry and wet state
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where approximately 24 % of growth factor was released,
followed by a slower release for the remaining 14 days.
The cumulative release was 50 % of initial loading by
day 14.
3.4 Chondrocytes and Gel-MCP (with
and without TGF-b1) cultured in pellet
The cell viability of chondrocytes seeded in crosslinked
Gel-MCP with and without TGF-b1 was examined by
MTS assay. The obtained results after 24 h and 7, 14 and
21 days of culture show a consistent viability of the cell
agglomerated with both, loaded and unloaded Gel-MCP
(Fig. 4). Comparing the pellet of Gel-MCP with TGF-b1
and the cell pellet (used in this case as control sample), the
cell viability was improved by the TGF-b1 released in
the culture medium. That is way the number of viable
chondrocytes remains almost constant after 21 days in the
case of TGF-b1 loaded Gel-MCP while viability after
1 week significantly decreased in both, unloaded Gel-MCP
pellet and in the cell pellet.
Chondrocyte morphology evaluated by SEM of both
cell/microparticle pellets (microparticles with and without
TGF-b1) and the control (cell pellet) (see Fig. 5) demon-
strated that after 1 and 7 days of culture, the cells adhered
very well on the surface of both types of microparticles
(with and without TGF-b1), forming interparticle cellular
bridges (indicated by white arrows). Cells have a round
morphology and can be distinguished from Gel-MCP by
the characteristic surface roughness. As a result, micro-
particles were bound together. A homogeneous layer of
chondrocytes, microparticles and ECM can be seen after
14 days of culture, in cell-TGF-b1 loaded microparticle
pellets. Some isolated cells emerge, with round morphol-
ogy (Fig. 5). Cell aggregates were also observed in the
constructs made with microparticles without TGF-b1. The
chondrocyte pellets revealed an elongated morphology
after 14 days of culture in chondrogenic medium.
The expression of type I collagen and aggrecans and the
actin cytoskeleton formation were examined by confocal
laser scanning microscopy (CLSM). Cell/Gel-MCP pellets
with and without TGF-b1 and cell pellets (reference) were
cross-sectioned in thick slices (*2 mm). CLSM images
after 14 and 21 days of culture are represented in Fig. 6.
Nuclei were counterstained with DAPI (blue) and the
expression of type I collagen and aggrecans was followed
by Alexa-488 (green) and 647 (red) linked to the secondary
antibody respectively. Positive expression of aggrecans
(red) was observed mainly in the cell pellet (control
material) and in the lesser extent in TGF-b1 loaded Gel-
MCP pellet, localized around the cells after 14 days. After
21 days of culture, the aggrecans expression was positive
for cell/Gel-MCP (with and without TGF-b1) pellet and
cell pellet. In chondrocyte pellets, used as control, the
secretion of type I collagen was clearly detected and pre-
dominantly on the surface of the cell pellet. On the con-
trary, in the cell/Gel-MCP (with and without TGF-b1) only
a few cells, even after 21 days, showed a positive staining.
Actin cytoskeleton was clearly detected in the cell pel-
lets after 14 and 21 days of culture in chondrogenic med-
ium compared to the cell/Gel-MCP pellets, where only in
some cells was observed.
Glycosaminoglycans and type II collagen are the most
important components of ECM in native articular cartilage;
their expression in 3D culture is a recognized criterion of
chondrogenecity. The results obtained in our constructs are
represented in Figs. 7 and 8 respectively. The differences
in GAG synthesis among the different supports are not
significant at 14 days, nevertheless at 21 days of culture
the amount of GAG per 20 mg of Gel-MCP is significantly
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Fig. 4 MTS assay for cell/gelatin microparticle pellets (with and
without TGF-b1) and cell pellets, used as reference. Asterisks denote
significant differences between samples on the same culture day.
Ampersand represent significant differences on different culture days.
Error bars represent means ± SD with n = 4
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higher in loaded microparticles than in unloaded micro-
particles or in the pellet.
Type II collagen synthesis was significantly increased
from 14 to 21 days (P \ 0.05) for cell/TGF-b1 loaded Gel-
MCP pellets being significantly higher than in the pellets or
in unloaded Gel-MCP.
In cell pellets, GAG content clearly decreases with the
culture time, while type II collagen deposition increase.
This feature could be due to a partial dissolution of GAG as
result of decrease of pellet size [21].
4 Discussion
Regeneration of articular cartilage with the technique of
autologous chondrocyte implant, ACI, has proved to be
able to produce newly formed cartilage tissue in the region
of the cartilage defect although the evolution of the tissue
with time present important drawbacks including the
degeneration of the tissue to fibrocartilage with poor
mechanical properties [22–24]. The implant of a mature
chondrocyte pellet in the cartilage defect in a rabbit model
also produced a cartilaginous tissue lacking the organiza-
tion of hyaline cartilage and with very low elastic modulus
after 3 months of implantation [25]. Culture of chondro-
cytes in a pellet in chondrogenic medium produce cells
with round morphology with production of ECM with
abundance of glycosaminoglycans and type II collagen, but
expressing negative markers for hyaline cartilage chon-
drocytes as type I collagen [26–28]. The presence of a
scaffolding system that supports cell adhesion and controls
stress transmission to the cells can improve the perfor-
mance of chondrocyte transplant to a cartilage defect. The
strategy proposed in this work is somewhere in between the
entrapping of chondrocytes in a gel such as alginate [29],
poly (ethylene oxide) [30], oligo poly(ethylene glycol)
fumarate [11, 31], poly (ethylene glycol dimethacrylate)
[32, 33], silk [34] extensively explored in the literature and
seeding the cells in a macroporous scaffold in which they
adhere to the pore walls a situation which is not far from
monolayer culture. The cell-microparticles suspension can
be injected in the zone of the cartilage following the
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Fig. 5 Scanning electron microscopy images of chondrocytes seeded
in TGF-b1 loaded Gel-MCP (left column), control sample (micro-
particles without TGF-b1) and cell pellet (right column) after 1, 7 and
14 days. Scale bars correspond to 40 lm. The white arrows indicate
interparticle cellular bridges. The black arrows indicate the Gel-MCP
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surgical approaches currently used in ACI practice, but
adding the required support for cell attachment.
In this study, we crosslinked Gel-MCP with genipin,
which was reported to be non cytotoxic and a safe cross-
linking agent, compared to commonly used glutaraldehyde
or formaldehyde crosslinkers [35]. Nevertheless, Wang
et al. [36] recently reported a certain toxicity of genipin on
chondrocytes and osteoblasts at high doses being its tox-
icity depended on doses but not on the time. Genipin has
been used as a culture medium supplement to develop
enhanced engineered cartilage [37]. Chitosan microparti-
cles crosslinked with genipin were also used to culture
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Fig. 6 Actin cytoskeleton (green) development and immunofluores-
cence staining for aggrecan (red) and type I collagen (green) of
chondrocytes/gelatin microparticle pellets (with and without TGF-b1)
and cell pellets cultured after 14 and 21 days in chondrogenic
medium. The scale bar represents 100 lm for all images. The cells
nuclei were counterstained with DAPI (blue) (Color figure online)
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mesenchymal stem cells in osteogenic medium during
14 days, showing no signs of toxicity [18]. In addition, the
results published by Solorio et al. [38] demonstrated the
potential of Gel-MCP crosslinked with genipin to deliver
growth factors locally to the cells.
The crosslinking reaction during the formation of
microparticles results in a 26 % crosslinking degree.
Crosslinking of already formed Gel-MCP can yield higher
crosslinking density as reported in the [39, 40]. The strat-
egy of this work was to prepare the water/oil emulsion in
PBS (pH 7.4) at 37 C using a mixture of biopolymer and
growth factor as aqueous phase. In this way an ionic
complex is formed between the acidic gelatin (isoelectric
point 5.0) and TGF-b1 (isoelectric point 9.5) [41] to which
genipin is added. It can be expected that some of the
growth factor molecules be linked to gelatin by covalent
bonds created by the crosslinker.
At 14 days the cumulative release of TGF-b1 is around
50 % (Fig. 3). Growth factor molecules fixed to the matrix
by covalent bonds would be delivered only by support
degradation at longer times. The significant differences in
chondrocyte response between TGF-b1 loaded and unloa-
ded microparticles supports that delivered growth factor is
bioactive.
Recent studies by Catela et al. [42] demonstrated that
TGF-b1 released from fibrin gels to which was covalently
bonded was bioactive inducing chondrogenic differentia-
tion of mesenchymal stem cells. Crosslinking considerably
reduce water uptake of Gel-MCP and improves their sta-
bility in aqueous medium. Crosslinking density can be used
to modulate the rate of sustained delivery of TGF-b1.
In this work we have shown that Gel-MCP agglomer-
ated together with the expanded chondrocytes create a 3D
environment, without the need of another gel embedding
both Gel-MCP and cells as proposed in other works
[10–12]. The construct is consistent and easily handleable,
due to the strong adhesion between the ECM produced by
the cells and the Gel-MCP. Interestingly enough, due to the
Gel-MCP/cells ratio these microparticles acts as a 3D
scaffold, favouring cell to matrix interaction with respect to
cell to cell contacts and even, without growth factor supply,
the behaviour of the seeded chondrocytes change signifi-
cantly with respect to the cell pellet: increased cell via-
bility, sharp diminution of type I collagen in the produced
ECM, absence of actin stress fibers in most of the cells, and
increased production of aggrecan. On the other hand, Gel-
MCP may act as a mean for stress transmission to the cells.
Acquisition and maintenance of the chondrocyte phenotype
‘‘in vivo’’ is highly addressed by dynamic compression
loading to which articular cartilage is subjected. The
transmission of these stresses to the cells in a pellet is quite
different to the situation in healthy cartilage where cells are
isolated in lacunae and protected by a quite hard tissue.
Crosslinked Gel-MCP can be produced with an elastic
modulus that can vary in a broad range, thus, it allows
designing the best conditions to create the adequate envi-
ronment with respect to compression load sustaining. On
the other hand, we have shown that sustained delivery of
TGF-b1 can be obtained from the cell/support agglomerate
itself, thus low amounts of the growth factor can be
delivered to the cells locally with small dissemination to
the rest of the organism. The improvement of cell behav-
iour in the culture with TGF-b1 delivery is very clear, with
increased viability and chondrogenic markers with respect
to the culture in non-loaded microspheres.
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Fig. 7 GAG quantification assay after chondrocyte/gelatin micropar-
ticle pellets (with and without TGF-b1) and cell pellets cultured for 2
and 3 weeks in chondrogenic medium. Asterisks denote significant
differences between samples on the same culture day. Ampersand
represent significant differences on different culture days. Error bars
represent means ± SD with n = 5
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Fig. 8 Collagen II content after chondrocyte/gelatin microparticle
pellets (with and without TGF-b1) and cell pellets cultured for 2 and
3 weeks in chondrogenic medium. Asterisks denote significant
differences between samples on the same culture day. Ampersand
represent significant differences on different culture days. Error bars
represent means ± SD with n = 5
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5 Conclusions
Cell/Gel-MCP constructs allow culture and redifferentia-
tion of mature chondrocytes previously expanded in
monolayer culture. Cell adhesion to microparticles
agglomerates the whole construct, which from the first day
of culture maintains coherence and can be easily handled.
TGF-b1 can be effectively included in the Gel-MCP during
their preparation by a water–oil emulsion process. Cross-
linking with genipin allows progressive delivery when the
particles are immersed in culture medium. Chondrocytes
culture in agglomerates with growth factor delivery show
viability for longer times, increased production of ECM
components characteristics of hyaline cartilage. The results
obtained indicate that the developed gelatin-based micro-
particles could be used as an injectable scaffold to delivery
chondrocytes through minimally invasive procedures, that
will agglomerate in situ by the action of the cells; the
particles are be able to provide mechanical and a 3D
structural support for the cells and also act as a system able
to release relevant bioactive molecules.
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